Founder & Chief Executive Officer
Paul Badawi is a Founder and Chief Executive Officer of Sight Sciences, Inc. He is a co-inventor of the OMNI™ Glaucoma Treatment System, VISCO™360 Viscosurgical System, TRAB™360 Trabeculotomy System, Helix™ Microstent, and TearCare®.
+ READ MORE
Prior to launching Sight Sciences, Paul led the U.S. healthcare venture capital practice for 3i Group, a global private equity firm. At 3i, Paul managed a portfolio of 12 medical device investments and $120MM invested. He served as a lead investor and board member for Ulthera (acquired by Merz), Xthetix (acquired by J&J), NeoGuide (acquired by Intuitive Surgical), OmniGuide, and Sotera Wireless, and as an observer on the boards of Small Bone Innovations (acquired by Stryker), Zonare (acquired by Mindray), and Transmedics.
Prior to entering the medical device world, Paul worked at the National Institutes of Health as a Research Fellow in the biochemical genetics laboratory of a Nobel Prize-winning scientist credited with cracking the genetic code.
Paul received a BS in Biological Sciences from the University of Chicago, an MBA from UCLA, and is a graduate of the Kauffman Fellows Program.
David Badawi, MD
Founder & Chief Technology Officer
Dr. David Badawi is a Founder and Chief Technology Officer of Sight Sciences, Inc. He is a co-inventor of the OMNI™ Glaucoma Treatment System, VISCO™360 Viscosurgical System, TRAB™360 Trabeculotomy System, Helix™ Microstent, and TearCare®.
+ READ MORE
David leads the company’s application and development of technology towards the treatment of the underlying causes of ophthalmic disease. He also oversees the preclinical and clinical development of each of the company’s products.
In addition to building Sight Sciences and helping to bring multiple innovative technologies to the operating room and the ophthalmology clinic, David runs a busy referral and surgical practice in the Chicago suburbs.
David received a BS in Microbiology from the University of Maryland and an MD from Georgetown University. He completed his residency in ophthalmology at the Jules Stein Eye Institute at UCLA and a cornea fellowship at Emory University.
Chief Financial Officer
Jesse Selnick is Chief Financial Officer of Sight Sciences, Inc. He brings to Sight Sciences more than 20 years of experience leading strategic growth, financing, capital allocation and operational initiatives for growing technology companies.
+ READ MORE
Most recently, Jesse served as Chief Financial Officer and on the Board of Directors of Electric Lightwave, an over $500 million revenue, private equity sponsored telecom infrastructure business, prior to its acquisition for $1.4B in 2017. At Electric Lightwave, Jesse led an approximately 100-person team responsible for corporate strategy, M&A, capital planning, treasury, accounting and tax, financial planning and analysis, business development, real estate and risk management.
Earlier in his career, Jesse served as a Managing Director at The Blackstone Group for approximately 10 years in its mergers and acquisitions advisory practice.
He holds a BS in Economics from The Wharton School at The University of Pennsylvania and an MBA from Harvard Business School.
Chief Commercial Officer
Shawn O’Neil is an ophthalmic industry veteran who leads Sight Sciences’ commercial activities and product launches. Previously, Shawn spent more than 20 years at Alcon, a global leader in eye care, where he covered both Ophthalmology and Optometry.
+ READ MORE
During his tenure at Alcon, he was responsible for developing commercial teams and strategies to launch novel and disruptive technologies including the Opti-Free RepleniSH Multi-Purpose Solution, EX-PRESS Glaucoma Filtration Device, LenSx Laser System, and CyPass Micro-Stent for glaucoma.
Shawn earned a bachelor’s degree in Economics from Princeton University.
Vice President of Sales, Surgical Glaucoma
Jeff Francis is responsible for leading the sales force for Sight Sciences’ surgical devices. Jeff has nearly 20 years of experience in the pharmaceutical, medical device and surgical arenas. Before joining Sight Sciences, Jeff was an associate regional sales director at Nestle Skin Health, a global leader in skin health and wellness.
+ READ MORE
Prior, Jeff held positions of increasing responsibility in sales training, sales leadership, marketing and hospital/corporate accounts at Alcon Laboratories, where he began his career. Jeff brings to Sight Sciences a passion and commitment for building, developing and empowering high performing sales teams.
Jeff holds a bachelor’s degree from the University of Kansas.
Ingrid Kane, MD
Vice president of Global Medical Affairs
Dr. Ingrid Kane is an ophthalmologist who, over the past twenty years, has demonstrated great success working with ophthalmic medical device companies in all stages of product development, clinical trial research, and commercialization. Before joining Sight Sciences, Ingrid spent a decade introducing an interventional surgical glaucoma procedure to surgeons in 25 countries around the world.
+ READ MORE
As Vice President of Medical Affairs at iScience Interventional and later at Ellex, Ingrid provided hundreds of didactics, wet labs, and hands-on surgical evaluations around the world for ab externo canaloplasty – one of the most technically challenging procedures in ophthalmology. Through her deep knowledge of ophthalmic physiology and disease and her personal approach to clinical training, Ingrid has formed very strong relationships and gained the trust of ophthalmic surgeons around the globe. Ingrid is applying this same level of clinical excellence and personalized training as she introduces Sight Sciences products and procedures to surgeons worldwide.Ingrid began her career in the ophthalmic industry after moving to the United States and joining Oculex Pharmaceuticals (ultimately acquired by Allergan). At Oculex, Ingrid was instrumental in the development of a commercially successful ophthalmic drug delivery systems and is a patent holder on Ozurdex, an intravitreal implant for the treatment of macular edema, diabetic macular edema, and uveitis.
Ingrid earned her medical degree at Charles University in Prague, Czech Republic and completed her ophthalmology training at the First Eye Clinic at Charles University.
Vice President of Marketing, Dry Eye
Todd Love oversees the marketing program for Sight Sciences’ dry eye product portfolio. He has extensive experience in the optometric industry spanning nearly 20 years in a variety of sales, marketing, and professional development leadership roles in which he consistently increased company value, delivered business results and successfully launched major global brands.
+ READ MORE
Todd joined Sight Sciences from Bausch + Lomb where he was Director, Professional Strategy and led the development of key opinion leaders, optometric institutions and professional programs. Prior, Todd held positions of increasing responsibility at Alcon Laboratories in sales, sales leadership, market development, global marketing and brand management where he led the company’s global contact lens care franchise. During his tenure at Alcon, he was awarded PM360’s Trailblazer Award for Industry Wide Marketing Innovation.
Todd holds a bachelor’s degree in business administration from the University of Houston.
Vice President of Research & Development
Daniel O’Keeffe leads the research and development efforts behind the company’s portfolio of surgical and non-surgical products. He is a co-inventor of the OMNI™ Glaucoma Treatment System, VISCO™360 Viscosurgical System, TRAB™360 Trabeculotomy System, Helix™ Microstent, and TearCare®.
+ READ MORE
Daniel has been instrumental in the successful growth and development of Sight Sciences since the company’s earliest days.
Prior to joining Sight Sciences and entering the world of ophthalmology, Daniel amassed over ten years of successful research and development product development experience in cardiovascular catheters, vascular surgery delivery systems and surgical instruments. Daniel has designed and developed innovative products for industry leaders such as Boston Scientific and smaller start-ups such as Aptus Endosystems.
Daniel received a BS in Mechanical Engineering from the California Polytechnic State University, San Luis Obispo.
Vice President of Manufacturing and Operations
John Ordway leads the manufacturing and operational efforts for Sight Sciences. John has over 25 years of experience in medical device manufacturing, supply chain, and operations management.
+ READ MORE
Prior to joining Sight Sciences, John was the Vice President of Operations for Moximed, a venture-backed orthopedic medical device company. Previously, he held senior positions managing supply chain, supplier quality, incoming inspection, manufacturing, and global distribution for commercially successful venture-backed start-ups including Angioscore (acquired by Spectranetics), St. Francis Medical (acquired by Kyphon/Medtronic), and Surgical Dynamics (acquired by Stryker). John began his career in manufacturing and supply chain management at Guidant.
Prior to entering the world of ophthalmology, John consistently helped develop and transition a variety of innovative medical devices in both orthopedics (knee implants, spinal fusion, discectomy, spinal stenosis) and cardiovascular (scoring balloon catheters, saphenous vein harvesting systems, and minimally invasive devices for general surgery) to full scale manufacturing.
John holds an MBA from Thunderbird School of Global Management and a BS in Political Science and Psychology from the University of Oregon.
Vice President of Clinical and Regulatory Affairs
Anne-Marie Ripley oversees the company’s clinical research, clinical trials, regulatory submissions and product approvals, and marketing studies across the company’s portfolio of ophthalmic medical devices. From 2005 to 2016, Anne-Marie served as Vice President of Clinical and Regulatory Affairs at Second Sight Medical Products through its IPO in 2015 (“EYES”).
+ READ MORE
At Second Sight, Anne-Marie successfully guided the world’s first implantable retinal prosthesis device to restore some vision in blind patients through FDA HDE approval, CE Mark, and commercialization in the United States, Europe, and Canada.
From 2002 to 2005, Anne-Marie worked for the Alfred E. Mann Foundation, a non-profit organization that was conducting research and development for innovative bionic devices for people suffering from disabilities due to stroke and spinal cord injury with a final position as Vice President of Clinical and Regulatory Affairs. Earlier in her career, she worked in clinical and regulatory affairs at Eclipse Surgical Technologies (now Cardiogenesis), a maker of interventional cardiology, cardiac surgery and orthopedic devices.
Anne-Marie received her Bachelor of Arts in Public Policy from Stanford University.
Vice President of Quality Assurance
Richard Rush is an experienced Quality Management executive with over 20 years in the medical device industry, working in companies ranging from small early stage start-ups to large established industry leaders. A former Vice President at Guidant Corporation, Richard has also held leadership positions at internationally respected ophthalmic device companies such as Alcon Laboratories and Coherent.
+ READ MORE
Richard consulted for Sight Sciences for several years before joining the company full-time in 2016. Richard has been instrumental in creating and managing the Sight Sciences Quality System and obtaining numerous regulatory approvals including the 510(k) clearances and CE Marking for the company’s surgical devices.
Richard received a BS in General Engineering from University of Illinois at Urbana-Champaign, an MBA from UC Berkeley, and is a long time member of the American Society for Quality.
Vice President of Marketing, Surgical Glaucoma
Patrick Smale leads the marketing program for Sight Sciences’ surgical portfolio. Before joining Sight Sciences, Patrick was Global Product Director, Surgical Glaucoma at Alcon Laboratories where he was responsible for the global launch of the CyPass Micro-stent.
+ READ MORE
In this role, Patrick led the market analytics and assessment, campaign development and lifecycle management activities for Alcon’s surgical glaucoma portfolio. Prior, he held positions of increasing responsibility and leadership in market research and business analytics covering the pharmaceutical, surgical and vision care businesses.
Patrick holds a bachelor’s degree in kinesiology and biology from Occidental College and an MBA from the University of Delaware, Lerner College of Business and Economics.